Literature DB >> 26373433

DYRK1A overexpression enhances STAT activity and astrogliogenesis in a Down syndrome mouse model.

Nobuhiro Kurabayashi1, Minh Dang Nguyen2, Kamon Sanada3.   

Abstract

Down syndrome (DS) arises from triplication of genes on human chromosome 21 and is associated with anomalies in brain development such as reduced production of neurons and increased generation of astrocytes. Here, we show that differentiation of cortical progenitor cells into astrocytes is promoted by DYRK1A, a Ser/Thr kinase encoded on human chromosome 21. In the Ts1Cje mouse model of DS, increased dosage of DYRK1A augments the propensity of progenitors to differentiate into astrocytes. This tendency is associated with enhanced astrogliogenesis in the developing neocortex. We also find that overexpression of DYRK1A upregulates the activity of the astrogliogenic transcription factor STAT in wild-type progenitors. Ts1Cje progenitors exhibit elevated STAT activity, and depletion of DYRK1A in these cells reverses the deregulation of STAT. In sum, our findings indicate that potentiation of the DYRK1A-STAT pathway in progenitors contributes to aberrant astrogliogenesis in DS.
© 2015 The Authors.

Entities:  

Keywords:  DYRK1A; Down syndrome; STAT; astrogliogenesis; neocortical progenitor

Mesh:

Substances:

Year:  2015        PMID: 26373433      PMCID: PMC4641506          DOI: 10.15252/embr.201540374

Source DB:  PubMed          Journal:  EMBO Rep        ISSN: 1469-221X            Impact factor:   8.807


  57 in total

Review 1.  Trisomy 21 and early brain development.

Authors:  Tarik F Haydar; Roger H Reeves
Journal:  Trends Neurosci       Date:  2011-12-09       Impact factor: 13.837

2.  Non-cell-autonomous action of STAT3 in maintenance of neural precursor cells in the mouse neocortex.

Authors:  Takeshi Yoshimatsu; Daichi Kawaguchi; Koji Oishi; Kiyoshi Takeda; Shizuo Akira; Norihisa Masuyama; Yukiko Gotoh
Journal:  Development       Date:  2006-05-25       Impact factor: 6.868

Review 3.  Cell types to order: temporal specification of CNS stem cells.

Authors:  Hideyuki Okano; Sally Temple
Journal:  Curr Opin Neurobiol       Date:  2009-05-06       Impact factor: 6.627

4.  A new expression cloning strategy for isolation of substrate-specific kinases by using phosphorylation site-specific antibody.

Authors:  R Matsuo; W Ochiai; K Nakashima; T Taga
Journal:  J Immunol Methods       Date:  2001-01-01       Impact factor: 2.303

5.  APP-dependent up-regulation of Ptch1 underlies proliferation impairment of neural precursors in Down syndrome.

Authors:  Stefania Trazzi; Valentina Maria Mitrugno; Emanuele Valli; Claudia Fuchs; Simona Rizzi; Sandra Guidi; Giovanni Perini; Renata Bartesaghi; Elisabetta Ciani
Journal:  Hum Mol Genet       Date:  2011-01-25       Impact factor: 6.150

Review 6.  Somatic mutation, genomic variation, and neurological disease.

Authors:  Annapurna Poduri; Gilad D Evrony; Xuyu Cai; Christopher A Walsh
Journal:  Science       Date:  2013-07-05       Impact factor: 47.728

7.  Risks of leukaemia and solid tumours in individuals with Down's syndrome.

Authors:  H Hasle; I H Clemmensen; M Mikkelsen
Journal:  Lancet       Date:  2000-01-15       Impact factor: 79.321

8.  Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease.

Authors:  W S Griffin; L C Stanley; C Ling; L White; V MacLeod; L J Perrot; C L White; C Araoz
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

Review 9.  The glial nature of embryonic and adult neural stem cells.

Authors:  Arnold Kriegstein; Arturo Alvarez-Buylla
Journal:  Annu Rev Neurosci       Date:  2009       Impact factor: 12.449

10.  Role of astroglia in Down's syndrome revealed by patient-derived human-induced pluripotent stem cells.

Authors:  Chen Chen; Peng Jiang; Haipeng Xue; Suzanne E Peterson; Ha T Tran; Anna E McCann; Mana M Parast; Shenglan Li; David E Pleasure; Louise C Laurent; Jeanne F Loring; Ying Liu; Wenbin Deng
Journal:  Nat Commun       Date:  2014-07-18       Impact factor: 14.919

View more
  18 in total

1.  DYRK1A regulates B cell acute lymphoblastic leukemia through phosphorylation of FOXO1 and STAT3.

Authors:  Rahul S Bhansali; Malini Rammohan; Paul Lee; Anouchka P Laurent; Qiang Wen; Praveen Suraneni; Bon Ham Yip; Yi-Chien Tsai; Silvia Jenni; Beat Bornhauser; Aurélie Siret; Corinne Fruit; Alexandra Pacheco-Benichou; Ethan Harris; Thierry Besson; Benjamin J Thompson; Young Ah Goo; Nobuko Hijiya; Maria Vilenchik; Shai Izraeli; Jean-Pierre Bourquin; Sébastien Malinge; John D Crispino
Journal:  J Clin Invest       Date:  2021-01-04       Impact factor: 14.808

2.  Inhibition of Dyrk1A Attenuates LPS-Induced Neuroinflammation via the TLR4/NF-κB P65 Signaling Pathway.

Authors:  Cheng Ju; Yue Wang; Caixia Zang; Hui Liu; Fangyu Yuan; Jingwen Ning; Meiyu Shang; Jingwei Ma; Gen Li; Yang Yang; Xiuqi Bao; Dan Zhang
Journal:  Inflammation       Date:  2022-08-02       Impact factor: 4.657

3.  Design, synthesis, and biological evaluation of polyphenol derivatives as DYRK1A inhibitors. The discovery of a potentially promising treatment for Multiple Sclerosis.

Authors:  Gian Luca Araldi; Yu-Wen Hwang
Journal:  Bioorg Med Chem Lett       Date:  2022-03-12       Impact factor: 2.940

Review 4.  DYRK1A: a down syndrome-related dual protein kinase with a versatile role in tumorigenesis.

Authors:  Amina Jamal Laham; Maha Saber-Ayad; Raafat El-Awady
Journal:  Cell Mol Life Sci       Date:  2020-09-01       Impact factor: 9.261

Review 5.  DYRK1A, a Dosage-Sensitive Gene Involved in Neurodevelopmental Disorders, Is a Target for Drug Development in Down Syndrome.

Authors:  Arnaud Duchon; Yann Herault
Journal:  Front Behav Neurosci       Date:  2016-06-03       Impact factor: 3.558

6.  4-Phenylbutyrate ameliorates apoptotic neural cell death in Down syndrome by reducing protein aggregates.

Authors:  Katsuya Hirata; Toshihiko Nambara; Keiji Kawatani; Nobutoshi Nawa; Hidetaka Yoshimatsu; Haruna Kusakabe; Kimihiko Banno; Ken Nishimura; Manami Ohtaka; Mahito Nakanishi; Hidetoshi Taniguchi; Hitomi Arahori; Kazuko Wada; Keiichi Ozono; Yasuji Kitabatake
Journal:  Sci Rep       Date:  2020-08-20       Impact factor: 4.379

7.  Inhibition of DYRK1A proteolysis modifies its kinase specificity and rescues Alzheimer phenotype in APP/PS1 mice.

Authors:  Benoît Souchet; Mickael Audrain; Jean Marie Billard; Julien Dairou; Romain Fol; Nicola Salvatore Orefice; Satoru Tada; Yuchen Gu; Gaelle Dufayet-Chaffaud; Emmanuelle Limanton; François Carreaux; Jean-Pierre Bazureau; Sandro Alves; Laurent Meijer; Nathalie Janel; Jérôme Braudeau; Nathalie Cartier
Journal:  Acta Neuropathol Commun       Date:  2019-03-18       Impact factor: 7.801

8.  Tau pathology reduction with SM07883, a novel, potent, and selective oral DYRK1A inhibitor: A potential therapeutic for Alzheimer's disease.

Authors:  Benoît Melchior; Gopi Kumar Mittapalli; Carolyn Lai; Karen Duong-Polk; Joshua Stewart; Bora Güner; Brian Hofilena; Amanda Tjitro; Scott D Anderson; David S Herman; Luis Dellamary; Christopher J Swearingen; K C Sunil; Yusuf Yazici
Journal:  Aging Cell       Date:  2019-07-03       Impact factor: 9.304

9.  A human isogenic iPSC-derived cell line panel identifies major regulators of aberrant astrocyte proliferation in Down syndrome.

Authors:  Keiji Kawatani; Toshihiko Nambara; Nobutoshi Nawa; Hidetaka Yoshimatsu; Haruna Kusakabe; Katsuya Hirata; Akira Tanave; Kenta Sumiyama; Kimihiko Banno; Hidetoshi Taniguchi; Hitomi Arahori; Keiichi Ozono; Yasuji Kitabatake
Journal:  Commun Biol       Date:  2021-06-14

Review 10.  DYRK1A Protein, A Promising Therapeutic Target to Improve Cognitive Deficits in Down Syndrome.

Authors:  Anis Feki; Youssef Hibaoui
Journal:  Brain Sci       Date:  2018-10-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.